Brief: Pharming Announces Positive Interim Analysis Data From Leniolisib's Open-Label Extension Study
15/12/2022 06:06
Dec 15 (Reuters) - Pharming Group NV PHAR.AS :
* ANNOUNCES POSITIVE INTERIM ANALYSIS DATA FROM OPEN-LABEL
EXTENSION STUDY OF LENIOLISIB IN PRESENTATION AT THE 64TH
AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND
EXPOSITION
* INTERIM ANALYSIS DEMONSTRATED LENIOLISIB TO BE WELL
TOLERATED
AND INDICATED DURABILITY OF EFFICACY RESULTS SEEN IN PHASE
II/III RANDOMIZED, CONTROLLED TRIAL
Source text for Eikon: ID:nCNW3x58sa
Further company coverage: PHAR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))